Analyst Ratings January 26, 2026

KBW Lifts Bar Harbor Bankshares Price Target to $35, Keeps Market Perform Rating

Analyst update follows quarter that beat on operating earnings driven by stronger PPNR and lower loan-loss provisions

By Avery Klein BHB
KBW Lifts Bar Harbor Bankshares Price Target to $35, Keeps Market Perform Rating
BHB

Keefe, Bruyette & Woods raised its price target on Bar Harbor Bankshares to $35 from $34 on Monday while retaining a Market Perform rating. The move followed quarterly results that delivered $0.93 in operating earnings per share, aided by improved pre-provision net revenue, a modest expansion in net interest margin, and lower loan loss provisions. KBW modestly raised its earnings outlook by about 1%, citing lower provisions and stronger fee income partly offset by higher expenses.

Key Points

  • KBW raised its price target on Bar Harbor Bankshares to $35 from $34 and kept a Market Perform rating.
  • Quarterly operating earnings came in at $0.93 per share, aided by stronger pre-provision net revenue and lower loan loss provisions; net interest margin expanded by 6 basis points.
  • Loan balances grew at a 2% linked-quarter annualized rate overall, with commercial loans up 8% annualized; KBW raised earnings estimates by about 1% citing slightly lower provisions and better fee income, partly offset by higher expenses.

Keefe, Bruyette & Woods increased its 12-month price target on Bar Harbor Bankshares (NYSE: BHB) to $35.00 from $34.00 on Monday, while leaving the stock's Market Perform rating unchanged.

The analyst action follows the bank's recent quarterly report, which showed operating earnings of $0.93 per share. Management's results were supported by a stronger-than-expected pre-provision net revenue, together with reduced loan loss provisions, which helped the quarter outperform analyst projections.

The bank's PPNR improvement was broad-based across its three business lines, with net interest income the primary contributor. Net interest margin widened by 6 basis points during the quarter, supporting NII growth within overall revenue performance.

On the lending side, Bar Harbor reported steady expansion in loan balances. Total loans increased at a 2% linked-quarter annualized rate, with commercial lending the most notable contributor, rising at an 8% annualized pace for the period.

Following the results, KBW adjusted its earnings model for Bar Harbor upward by roughly 1%. The firm said the revision reflects expectations for slightly lower provisions and improved fee income, which are expected to be partially offset by higher operating expenses.

Independent analyst revisions also point to a modest upward trend in near-term earnings expectations, with market data showing two analysts have recently increased their forecasts for the upcoming period.

KBW's decision to nudge the price target higher while maintaining a Market Perform stance signals a cautious view that recognizes recent momentum in revenue and provisions, but which keeps the bank's valuation in a neutral category pending further operational evidence.


Context and implications

The change in KBW's estimate is relatively small in magnitude, reflecting incremental improvement in key metrics rather than a material shift in the bank's outlook. The drivers cited by KBW - lower provisions, better fee income and higher expenses - are consistent with the components reported in the quarter.

Risks

  • Provision expense sensitivity - if loan loss provisions reverse higher, earnings could be pressured; this risk primarily affects the banking and financials sectors.
  • Expense growth - KBW notes higher expenses are offsetting some revenue gains, introducing uncertainty around operating leverage for the bank and the regional banking sector.
  • Fee income variability - expected improvement in fee income was a factor in estimates; weaker-than-expected fee revenue would affect near-term earnings projections, impacting financials and banking services.

More from Analyst Ratings

Palantir Gains After Lofty 2026 Guidance; Analysts Split on Outlook Feb 2, 2026 Freedom Capital Markets Starts Coverage of Nebius Group With Buy Rating, $108 Target Feb 2, 2026 Clear Street Starts Coverage on Caribou Biosciences with Buy Rating and $13 Target Feb 2, 2026 Goldman Keeps OLN Neutral at $22 as Olin Signals Rough Q1, Cost Cuts to Cushion Results Feb 2, 2026 Aletheia Capital Starts Coverage on Teradyne With Buy Rating, $400 Target Feb 2, 2026